Table 1.

Characteristics and outcomes of patients with mucosal leishmaniasis treated with liposomal amphotericin B^*

Sex/age, years	Lesion site	Previous treatment	Contraindication(s)†	Total cumulative dose, mg	Weight, Kg	Dose mg/Kg	Outcome	Duration of hospital stay/follow-up
1 M/64	Nasal septum	None	AVR	2100	65	32.3	Cure	15 days/8 months
2 M/40	Nasal septum	None	AVR	2910	100	29.1	Cure	15 days/9 months
3 M/84	Nasal septum	None	AVR, CRF	2000	70	28.6	Cure	23 days/40 months
4 M/76	Nasal septum	(2 years earlier)	AVR, ARF	3000	60	50	Cure	21 days/37 months
5 M/47	Palate, larynx	(3 years earlier)	AVR, DM	3000	60	50	Cure	40 days/35 months
6 M/66	Nasal septum	(9 days earlier)	ARF	2600	68	38.2	Cure	24 days/25 months
7 M/35	Nasal septum, palate	(10 days earlier)	AVR	2250	85	26.5	Cure	21 days/40 months
8 M/52	Nasal septum, palate	(5 days earlier)	ARF	2240	93	24	Cure	14 days/7 months
Mean				25,125	75,125	34.83		21,625 days/25,125 months

^*ARF = acute renal failure; AVR = altered ventricular repolarization; CRF = chronic renal failure; DM = diabetes mellitus.

^†Contraindications to the use of antimonials, pentamidine, or deoxycholate amphotericin B.